Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-04
2005-01-04
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S018700, C514S019300, C514S396000, C514S401000, C548S335100, C548S337100, C530S331000
Reexamination Certificate
active
06838475
ABSTRACT:
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 6407066 (2002-06-01), Dressen et al.
patent: WO 9817679 (1998-04-01), None
patent: WO 0009543 (2000-02-01), None
Shiba, Tetsuo Bulletin of the Chemical Society of Japan 41(11), 2748-53, 1968.*
Szirtes Journal of Medicinal Chemistry 29(9), 1654-8, 1986.
Arasappan Ashok
Ganguly Ashit K.
Girijavallabhan Viyyoor Moopil
Njoroge F. George
Parekh Tejal
Kalyanaraman Palaiyur S.
Low Christopher S. F.
Lukton David
Schering Corporation
LandOfFree
Imidazolidinones as NS3-serine protease inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolidinones as NS3-serine protease inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidinones as NS3-serine protease inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398545